Your Australia-UK FTA: GenesisCare
- Company founded: 2005
- Approx. employees (worldwide): 5,000
- Approx. employees (Australia): 1,500 clinical staff in Australia
- Australian HQ: Sydney
GenesisCare is a leading provider of private cancer care in Australia and the UK. With 5000 highly trained healthcare professionals and support staff in Australia, the U.K., Spain, China and the United States, GenesisCare designs innovative treatments to care for people with all types of cancer and heart disease. Across the globe, GenesisCare sees more than 400,000 patients over 440 specialised care centres, offering diagnostics, radiotherapy, chemotherapy, cardiology and sleep services.
In the UK, GenesisCare aims to create partnerships with leading healthcare organisations, vendors and partners including the National Health Service, to support improvement in the oncology pathway across the UK. It is already one of the leading independent providers of advanced and innovative radiotherapy and cancer therapies. This includes installing the UK’s first MRIdian system for MRI-guided radiotherapy, revolutionising treatment for difficult-to-treat tumours such as central lung and pancreatic. In July 2020 GenesisCare is launching a new oncology centre in London, which will be the most advanced radiotherapy centre in Europe.
GenesisCare believes the Australia-UK Free Trade Agreement will be important for supporting high standards of healthcare and encouraging innovation in new medical technologies. It hopes the FTA will increase the movement of healthcare talent across the two countries and enhance recognition of professional qualifications.
James McArthur, General Manager of GenesisCare UK says that exchanging talent and expertise between Australia and the UK will deliver on the shared priority of improving patient outcomes:
“GenesisCare is built on the foundations of improving access to the best possible healthcare, by bringing together the skills, expertise and vision of leading health professionals and investing in world-class innovations.
The FTA will help us to boost this collaboration and deliver on our objectives by enhancing our ability to develop and market innovative technologies, expand our operations and move our talent where we need it to improve outcomes for many cancer patients.”
Case study produced in partnership with with the Australia-UK Chamber of Commerce and the Australian High Commission in the UK.